# Tumor DNA shedding and negative plasma results

Source: https://onco.cc/terms/ctdna-shedding-negative-results/  
OnCo record `ctdna-shedding-negative-results` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A tumor may release too little DNA into the sampled blood for a test to detect. A negative plasma result needs to be read with the test, sample and clinical setting in mind.

## Summary

A primary study across multiple cancers found that circulating tumor DNA detection varied by cancer type and stage. Assay capability and biological availability of tumor DNA both affect a result. A negative plasma call can reflect low shedding, limited sampled material or absence of the tracked signal, rather than proving that no tumor exists. This concept explains a limitation; it does not specify which additional clinical test an individual should receive.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: ctDNA shedding; uninformative negative plasma test; low-shedding tumors

## Sources

- Circulating tumor DNA detection across cancer types and stages (2014): https://doi.org/10.1126/scitranslmed.3007094
- Molecular recovery and error suppression study (2016): https://doi.org/10.1038/nbt.3520

## Connected records

- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Detection and quantification limits](https://onco.cc/terms/detection-versus-quantification/), [Evidence from measurement to patient benefit](https://onco.cc/terms/measurement-to-benefit-evidence/), [Finite-molecule sampling in blood tests](https://onco.cc/terms/finite-molecule-sampling/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/)

---
JSON: https://onco.cc/api/v1/entities/ctdna-shedding-negative-results.json